



Indiana Drug Utilization Review Board

January, 1998

Issue No. 3



DUR Board Seeks Input and Participation

Board Requests Input from Experts

The Medicaid DUR Board faces a significant challenge with regard to deliberations regarding not only criteria for prospective and retrospective drug use review but also mandated educational activities.

Clearly the Board itself cannot have encyclopedic knowledge and practical experience in all areas of medicine and pharmacy. In recognition of this and with a real sense of urgency to fulfill our duties, the Board is requesting the formation of a voluntary advisory panel. Physicians, pharmacists and pharmacologists who would like to share their expertise and some of their time on an ad hoc basis would add to the quality of our decisions. Hopefully this will improve the delivery of the pharmaceutical care in Indiana. The DUR Board would like to begin focusing on the following areas:

- **Heart Failure**
- **Anti-Coagulation**
- **Asthma**

Along with the Board's current mandated duties, we would also like to see a system which is more supportive and less burdensome on providers. Currently we are requesting advice on OTC products that impact patients with renal impairment. Individuals with interests in this or other areas can reply to the board at the address listed below. We are also attempting to establish a web site to facilitate communications. Comments regarding any and all aspects of the DUR Board would be greatly appreciated.



The Indiana Drug Utilization Review Newsletter is prepared by the Indiana DUR Board, Office of Medicaid Policy and Planning and EDS. Any comments or suggestions should be forwarded to:

**Indiana DUR Board
402 West Washington St.
Room W382
Indianapolis, Indiana 46204**

ATTENTION

The DUR board is seeking practitioners who specialize in renal disease to help with the OTC formulary revision. Board members have learned that renally compromised patients may have the need for calcium and phosphorus supplements not currently included in the formulary. Practitioners may provide input by writing to the DUR Board

EXTRA...

The Indiana Medicaid DUR Board requests your assistance in reviewing the potential drug-drug interaction of dextromethorphan and MAOI's. If you are aware of an adverse experience, please contact the Board at the above address.

Your Indiana DUR Board

Thomas Bright, M.D.

Doctor Tom Bright received his Medical Degree from the University of Kentucky College of Medicine in Lexington, Kentucky. He was the Vice Chair of the Indiana DUR Board from 1993-1996, and is currently the Chair of the DUR Board. Along with the DUR Board, Dr. Bright is also involved with the Tuberculosis Medical Advisory Committee with the Indiana State Board of Health, a consultant to the Indiana Poison Center and a Clinical Affiliate Professor in Clinical Pharmacy at Purdue University. In Indiana, he is affiliated with St. John's Medical Center; Wishard Memorial Hospital; Riverview Hospital; Indiana University Hospitals; St. Vincent Hospital; and Community Hospital. Dr. Bright is board certified with the American Board of Internal Medicine, Critical Care Medicine-American Board of Internal Medicine and Pulmonary Medicine-American Board of Internal Medicine.

Sharon Hammerich, Pharm. D., R.Ph.

Doctor Sharon Hammerich received her Doctor of Pharmacy degree from the University of Southern California in Los Angeles. Dr. Hammerich is an Associate Professor of Pharmacy Practice at Butler University College of Pharmacy and Health Sciences. As a member of the Ribordy Center for Community Pharmacy Practice, she works to develop the patient care services provided by community pharmacists. Dr. Hammerich is a member of the American Pharmaceutical Association, Indiana Pharmacist Association, California Society of Health-System Pharmacists, Leadership America and Smiles Unlimited Universal Clown Ministry. Dr. Hammerich has been a member of the Indiana DUR Board since 1993, and currently serves as its Vice Chair.

Neil Irick, M.D.

Doctor Neil Irick received his Medical Degree from Indiana University School of Medicine in Indianapolis, Indiana. He has been a member of the Indiana DUR Board since 1993. He is currently the President of Pain Management Consultants and also the Associate Medical Director of Odyssey Hospice. Dr. Irick has been appointed the Clinical Assistant Professor of Internal Medicine at the Indiana University School of Medicine and the Adjunct Assistant Professor of Nursing for the Indiana University School of Nursing. Dr. Irick is involved with numerous professional organizations including the American Medical Association; the Indiana State Medical Association; a State Delegate of the Indianapolis Medical Society; the International Association for the Study of Pain; and the National Hospice Organization.

Vicki Poole-Hoffmann, R.Ph., Pharm.D.

Doctor Vicki Poole-Hoffmann received her Pharmacy degree and her Doctorate in Pharmacy from Purdue University in West Lafayette, Indiana. She also has her MBA from Indiana University in Indianapolis, Indiana. She is currently the Executive Director of Vitalink. Dr. Poole-Hoffmann has been a member of the Indiana DUR Board since 1993. She has been appointed to numerous other groups including an Affiliate Instructor of Pharmacy Practice at Butler University and an Affiliate Assistant Professor of Clinical Pharmacy at Purdue University. She is currently affiliated with the Midwest Regional Consultant Pharmacist Conference as Co-chair; Member of the Board of Directors for the American Society of Consultant Pharmacists and also the Dean's Professional Council at Purdue University.

Terry Lindstrom, Ph.D.

Doctor Terry Lindstrom received his Ph.D. in Pharmacology at the University of Minnesota in Minneapolis, Minnesota. He is currently the Research Advisor for the Drug Metabolism and Disposition Department for Lilly Research Laboratories-A Division of Eli Lilly and Company. Dr. Lindstrom is also an Adjunct Assistant Professor of the Department of Pharmacology and Toxicology for the Indiana University School of Medicine. He has been a member of the Indiana DUR Board since 1993. Dr. Lindstrom is a member of the American Society of Pharmacology and Experimental Therapeutics; the

Your Indiana DUR Board

International Society for the Study of Xenobiotics; the Society of Toxicology; the American Association of Pharmaceutical Scientists (AAPS) and the Indianapolis/Cincinnati Discussion Group, AAPS.

Diana Simon-Mimms, M.D.

Doctor Diana Simon-Mimms received her Medical Degree from Indiana University in Indianapolis. She is currently a Clinical Assistant Professor in the Department of Psychiatry and Chief Medical Officer at Larue Carter Hospital. Dr. Simon-Mimms completed her adult psychiatry residency at IU and her child psychiatry fellowships at Children's Hospital National Medical Center in Washington, D.C., and IU. Prior to joining IU, she was Medical Director of Child and Adolescent Psychiatry Services at Methodist Hospital. Her primary interest is physician executive/medical management. She has been a member of the Indiana DUR Board since 1996.

***Dr. Diana Simon-Mimms has resigned her position on the DUR Board as of 12/97. The Board will be actively pursuing a replacement.**

Thomas A. Smith, P.D., M.S., F.A.S.C.P.

Mr. Tom Smith received his Pharmacy Degree and his Master of Science in Rehabilitation Psychology from Purdue University in West Lafayette, Indiana. He is currently in private practice of Psychotherapy, specializing in Pain Management and is also the President and Chief Executive Officer of Smith Rehabilitation Consultants. Mr. Smith also practices for OSCO Drug. He is a member of numerous associations including the American Counseling Association; American Rehabilitation Counselors Associations; American Mental Health Counselors Association; Association for Adult Development and Aging; and Fellow, American Society of Consultant Pharmacists. He has been a member of the Indiana DUR Board since the beginning of 1997.

Patricia A. Treadwell, M.D.

Doctor Patricia Treadwell received her Medical Degree from Cornell University Medical College in New York, New York. She is currently on the Medical Staff at Indiana University Hospitals and Wishard Memorial Hospital, and also an Associate Professor for the Departments of Dermatology and Pediatrics. She currently finished a two year term as President for the National Medical Association, Dermatology Section. Dr. Treadwell is a member of numerous associations including the Alpha Omega Alpha Medical Honor Society; American Academy of Dermatology; American Academy of Pediatrics; Indiana Dermatology Society and the Women's Dermatologic Society. She has been a member of the Indiana DUR Board since 1993.

G. Thomas Wilson, R.Ph., J.D.

Mr. Thomas Wilson received his Pharmacy Degree at Purdue University in West Lafayette, Indiana and his Law Degree from the Indiana University School of Law in Indianapolis, Indiana. He is currently the Co-Director of the Office of Experiential Programs, School liaison to the Indiana Board of Pharmacy and a Lecturer in Pharmacy Law at Purdue University's School of Pharmacy and Pharmacal Sciences. Mr. Wilson has presented more than 140 continuing education programs. He is a member of numerous Associations including the American and Indiana Bar Associations; Indiana Pharmacists Association; Indiana Society of Hospital Pharmacists; American Association of Colleges of Pharmacy; and the American Society for Pharmacy Law. He has been a member of the Indiana DUR Board since the summer of 1997.

**INDIANA MEDICAID DUR BOARD REPORT
TOP 25 LEGEND DRUGS BY \$ PAID**

| RANKING | NDC | DRUG NAME | STRENGTH | DOSAGE FORM | TOTAL PAID CLAIMS | AVERAGE QUANTITY/ PAID CLAIM | NUMBER CLAIMS PAID | AVERAGE \$/PAID CLAIM |
|---------|------------|-----------------|----------|-------------|-------------------|---------------------------------|--------------------|-----------------------|
| 1 | 00944-2938 | RECOMBINATE | 801-1240 | AHFU VIAL | \$3,375,309.92 | 6,589 | 490 | \$6,888.39 |
| 2 | 61113-0742 | PRILOSEC | 20 MG | CAPSULE | 1,706,365.06 | 35 | 14,822 | 115.12 |
| 3 | 00053-7668 | MONONINE | 1000U | VIAL | 1,382,292.98 | 8,357 | 167 | 8,277.20 |
| 4 | 00002-4117 | ZYPREXA | 10 MG | TABLET | 1,245,690.31 | 39 | 4,558 | 273.30 |
| 5 | 00777-3105 | PROZAC | 20 MG | PULVULE | 1,097,559.63 | 44 | 11,898 | 92.25 |
| 6 | 54129-0222 | FEIBA VH IMMUNO | 400-800U | VIAL | 917,239.08 | 6,074 | 129 | 7,110.38 |
| 7 | 00173-0344 | ZANTAC | 150 MG | TABLET | 650,105.87 | 55 | 8,126 | 80.00 |
| 8 | 00002-3144 | AXID | 150 MG | PULVULE | 603,156.26 | 53 | 8,065 | 74.79 |
| 9 | 00053-7668 | MONONINE | 250U | VIAL | 542,077.79 | 8,828 | 62 | 8,743.19 |
| 10 | 00078-0127 | CLOZARIL | 100 MG | TABLET | 499,771.58 | 30 | 5,272 | 94.80 |
| 11 | 00300-3046 | PREVACID | 30 MG | CAPSULE | 463,270.52 | 34 | 4,460 | 103.87 |
| 12 | 50458-0330 | RISPERDAL | 3 MG | TABLET | 462,949.95 | 57 | 2,231 | 207.51 |
| 13 | 00074-6215 | DEPAKOTE | 500 MG | TABLET | 450,077.19 | 91 | 4,497 | 100.08 |
| 14 | 00029-3211 | PAXIL | 20 MG | TABLET | 415,641.97 | 36 | 6,209 | 66.94 |
| 15 | 00049-4900 | ZOLOFT | 50 MG | TABLET | 409,038.27 | 35 | 6,068 | 67.41 |
| 16 | 00002-4115 | ZYPREXA | 5 MG | TABLET | 404,811.66 | 36 | 2,406 | 168.25 |
| 17 | 00944-2935 | HEMOFIL-M | 200-1500 | AHFU VIAL | 365,721.31 | 6,404 | 71 | 5,151.00 |
| 18 | 50458-0300 | RISPERDAL | 1 MG | TABLET | 357,768.48 | 45 | 4,230 | 84.58 |
| 19 | 00045-0659 | ULTRAM | 50 MG | TABLET | 351,590.92 | 60 | 9,436 | 37.26 |
| 20 | 00049-4910 | ZOLOFT | 100 MG | TABLET | 350,644.56 | 37 | 4,770 | 73.51 |
| 21 | 00006-0963 | PEPCID | 20 MG | TABLET | 334,615.34 | 50 | 4,594 | 72.84 |
| 22 | 00085-0458 | CLARITIN | 10 MG | TABLET | 319,541.94 | 29 | 5,804 | 55.06 |
| 23 | 50458-0430 | PROPULSID | 10 MG | TABLET | 300,754.68 | 101 | 4,787 | 62.83 |
| 24 | 50458-0320 | RISPERDAL | 2 MG | TABLET | 289,575.90 | 49 | 1,905 | 152.01 |
| 25 | 00944-2938 | RECOMBINATE | 401-800 | AHFU VIAL | 276,007.80 | 5,674 | 46 | 6,000.17 |

* Based on legend drug claims paid in 3Q1997

*Report is for drugs only - excludes medical supplies

*Report excludes compound drugs

*Data is from drug claim forms only, excludes inpatient hospital drug data